Search
Selected Filter
Displaying 1–10 of 227 diseases results
-
My Journey with Retinitis Pigmentosa and the Foundation Fighting Blindness
Beacon StoriesZach was diagnosed with Bardet-Biedl syndrome (BBS) through genetic testing from the Foundation’s My Retina Tracker® Program. Today, he is looking ahead with purpose — supporting research through the Foundation, planning for his future, and encouraging others to do the same.
-
Answers at Last: How Genetic Testing Revealed Zach’s Bardet-Biedl Syndrome
Beacon StoriesFor years, Zach Lovell lived with vision loss that didn’t have a complete explanation. Genetic testing through the Foundation’s My Retina Tracker® Program revealed he had Bardet-Biedl syndrome (BBS), finally connecting decades of health challenges and bringing long-awaited clarity to him and his family. Today, Zach is looking ahead with purpose — supporting research through the Foundation, planning for his future, and encouraging others to do the same.
-
Opus Genetics Launches Gene Therapy Clinical Trial for Best Disease
Research NewsThe Foundation funded preclinical studies for the approach and launched Opus.
-
Foundation Fighting Blindness Provides Public Access to Data From its RUSH2A Natural History Study
Foundation NewsRUSH2A has captured extensive data over four years from patients with USH2A mutations causing non-syndromic retinitis pigmentosa and Usher syndrome type 2A.
-
Eye on the Cure Podcast | Episode 94: Dr. Victoria Claire
Eye on the CureDr. Claire is a blind professional artist in contemporary sculpture.
-
SparingVision Launches Clinical Trial for Therapy to Re-Activate Dormant Cones in Advanced RP
Research NewsThe approach may provide better visual acuity than current optogenetic therapies in clinical trials.
-
Eye on the Cure Podcast | Episode 93: Sam Seavey
Eye on the CureSam Seavey talks about his journey with Stargardt disease.
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
-
Research News
Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.
-
Eye on the Cure Podcast | Episode 92: Lance Baldo, MD
Eye on the CureLance Baldo, MD, CEO at Beacon Therapeutics, is discussing his company’s gene therapy for XLRP.
.png)
.png)
